EXCERPT

But while health advocates expected Myriad's dominance of testing in this area to be over, Myriad and its lawyers see things quite differently. The Supreme Court's allowance of patents on another type of genetic material – cDNA – means that Myriad can still stop competitors from offering specific types of tests relating to the genes. It has other, differently worded patents that the competing tests are still infringing, according to Myriad lawyers.

The company is still flush with genetic patents it says remain valid. It originally owned 520 valid patent claims, and the Supreme Court decision merely "reduc[ed] the overall patent estate to 24 patents and 515 patent claims," lawyers wrote in documents filed Tuesday and Wednesday.

SOURCE

http://arstechnica.com/tech-policy/2013/07/myriad-fresh-off-supreme-court-loss-keeps-on-suing-over-gene-patents/